| Identification | Back Directory | [Name]
BC13 | [CAS]
3036645-03-8 | [Synonyms]
BC13
Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-cyclopentyl-2-[2-[4-(3,4-dihydro-5,7-dimethoxy-4-oxo-2-quinazolinyl)benzoyl]-2,7-diazaspiro[3.5]non-7-yl]-5-methyl- | [Molecular Formula]
C37H39N7O5 | [MOL File]
3036645-03-8.mol | [Molecular Weight]
661.75 |
| Chemical Properties | Back Directory | [Boiling point ]
881.703±75.00 °C(Press: 760.00 Torr)(predicted) | [density ]
1.447±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | [solubility ]
Chloroform: Sparingly Soluble: 1-10 mg/ml |
| Hazard Information | Back Directory | [Description]
BC13 is a dual inhibitor of cyclin-dependent kinase 6 (Cdk6) and bromodomain-containing protein 4 (BRD4; IC50s = 36.03, 234.12, and 137.42 nM for Cdk6 and BRD4 bromodomain 1 (BD1) and BD2), respectively).1 It is selective for Cdk6 over Cdk1-Cdk5 at 500 nM and for BD1 and BD2 in BRD4 over those in BRD2 and BRD3 (IC50s = >1,000, >1,000, 863.41, and 967.5 nM, respectively). It inhibits the proliferation of MDA-MB-231 and BT-549 triple-negative breast cancer (TNBC) cells (IC50s = 2,250 and 980 nM, respectively) but not non-cancerous MCF-10A cells (IC50 = >16.1 μM). BC13 (2 μM) in combination with the ferroptosis inducer RSL3 (Item No. 19288) synergistically reduces colony formation of MDA-MB-231 cells. It also reduces tumor growth in an MDA-MB-231 mouse xenograft model when administered at a dose of 25 mg/kg every other day.WARNING This product is not for human or veterinary use. | [References]
[1] YONGLEI ZHANG, XIAOBING WANG* Discovery of Dual CDK6/BRD4 Inhibitor Inducing Apoptosis and Increasing the Sensitivity of Ferroptosis in Triple-Negative Breast Cancer[J]. Journal of Medicinal Chemistry, 2024, 67 23: 21186-21207 21186-21207. DOI: 10.1021/acs.jmedchem.4c0197610.1021/acs.jmedchem.4c01976 |
|
|